Advanced Therapy Medicinal Products CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Phase, By Indication, By Region and Competition, 2020-2030F

Description

Global Advanced Therapy Medicinal Products CDMO Market was valued at USD 5.12 Billion in 2024 and is expected to reach USD 8.87 Billion by 2030 with a CAGR of 9.54% during the forecast period. The Global Advanced Therapy Medicinal Products CDMO Market is a dynamic and rapidly evolving sector within the pharmaceutical and biotechnology industries. This market encompasses organizations that provide specialized services for the development and manufacturing of advanced therapy medicinal products (ATMPs), which include gene therapies, cell therapies, and tissue-engineered products.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 5.12 Billion
Market Size 2030	USD 8.87 Billion
CAGR 2025-2030	9.54%
Fastest Growing Segment	Oncology
Largest Market	North America

Key Market Drivers

Proliferation of Advanced Therapies

The healthcare landscape is witnessing a revolution as advanced therapies, including gene therapies, cell therapies, and tissue-engineered products, emerge as groundbreaking treatments for previously incurable diseases. This paradigm shift in medicine is driving the demand for specialized services provided by Contract Development and Manufacturing Organizations (CDMOs).

The advent of advanced therapies has expanded therapeutic horizons, offering new hope to patients suffering from rare and debilitating conditions. These therapies target the root causes of diseases at the genetic and cellular levels, promising higher efficacy and fewer side effects compared to traditional treatments. As more conditions become treatable through advanced therapies, the demand for CDMO services to develop and manufacture these products increases.

Pharmaceutical companies, biotechnology firms, and academic institutions are investing heavily in advanced therapy research and development. This surge in investment translates into a growing pipeline of potential therapies. CDMOs are integral to this process, providing the expertise and infrastructure needed to advance these therapies from the laboratory to clinical trials and eventual commercialization.

The development and manufacturing of advanced therapies come with complex regulatory challenges. Regulatory bodies like the FDA and EMA have stringent requirements to ensure the safety and efficacy of these novel treatments. CDMOs specializing in advanced therapies possess the regulatory expertise to help clients navigate this intricate landscape, ensuring compliance throughout the product lifecycle. This support streamlines the regulatory approval process, accelerating market entry.

Key Market Challenges

High Costs

The development and manufacturing of advanced therapies, such as ATMPs (Advanced Therapy Medicinal Products), are inherently resource-intensive. These therapies require significant investment in research and development, with cutting-edge technology and highly specialized expertise necessary for their creation. The costs associated with preclinical and clinical trials, regulatory approvals, and the production of these therapies can often be prohibitively high, which poses a challenge for Contract Development and Manufacturing Organizations (CDMOs) involved in the production process. Furthermore, the advanced nature of these products demands high-quality standards, specialized facilities, and skilled personnel to ensure safety, efficacy, and compliance with stringent regulations. CDMOs must find innovative ways to streamline production processes, optimize resource allocation, and implement cost-control strategies without compromising the quality of the therapies being developed. Balancing cost efficiency while meeting the demands for high-end manufacturing processes is a critical challenge in the ATMP sector, and finding sustainable solutions is key to ensuring the long-term success of these products.

Key Market Trends

Increased Collaboration and Partnerships

Collaboration is increasingly becoming a critical driver of innovation within the Advanced Therapy Medicinal Product (ATMP) sector. As the complexity and scope of these therapies continue to grow, Contract Development and Manufacturing Organizations (CDMOs) are recognizing the importance of strategic partnerships with pharmaceutical companies, biotech startups, and academic institutions. These alliances allow stakeholders to pool resources, share knowledge, and co-develop cutting-edge therapies that may otherwise be challenging to create independently. In February 2022, Recipharm AB successfully finalized its acquisition of Vibalogics. Through this arrangement, Recipharm is set to gain valuable expertise in biologics, harnessing Vibalogics' capabilities in areas such as viral vaccines, oncolytic viruses, and gene treatments using viral vectors. This strategic move is expected to provide Recipharm with a substantial diversification of its offerings across various technologies and modalities.

Key Market Players

Celonic AG
Rentschler Biopharma SE
Catalent, Inc.
Lonza Group AG
WuXi Advanced Therapies
Minaris Regenerative Medicine, LLC
Pluri Biotech Ltd.
REPROCELL USA Inc.
BioPhorum Operations Group
Cellares Corporation

Report Scope:

In this report, the Global Advanced Therapy Medicinal Products CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Advanced Therapy Medicinal Products CDMO Market, By Product:

Gene Therapy
Cell Therapy
Tissue Engineered
Others

Advanced Therapy Medicinal Products CDMO Market, By Phase:

Phase I
Phase II
Phase III
Phase IV

Advanced Therapy Medicinal Products CDMO Market, By Indication:

Oncology
Cardiology
Central Nervous System
Musculoskeletal
Infectious disease
Immunology & inflammation
Others

Advanced Therapy Medicinal Products CDMO Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Advanced Therapy Medicinal Products CDMO Market.

Available Customizations:

Global Advanced Therapy Medicinal Products CDMO market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Advanced Therapy Medicinal Products CDMO Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others)
- 5.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
- 5.2.3. By Indication (Oncology, Cardiology, Central Nervous System, Musculoskeletal, Infectious disease, Immunology & inflammation, Others),
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America Advanced Therapy Medicinal Products CDMO Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Phase
- 6.2.3. By Indication
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Advanced Therapy Medicinal Products CDMO Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Phase
    - 6.3.1.2.3. By Indication
- 6.3.2. Canada Advanced Therapy Medicinal Products CDMO Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Phase
    - 6.3.2.2.3. By Indication
- 6.3.3. Mexico Advanced Therapy Medicinal Products CDMO Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Phase
    - 6.3.3.2.3. By Indication

7. Europe Advanced Therapy Medicinal Products CDMO Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Phase
- 7.2.3. By Indication
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Advanced Therapy Medicinal Products CDMO Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Phase
    - 7.3.1.2.3. By Indication
- 7.3.2. United Kingdom Advanced Therapy Medicinal Products CDMO Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Phase
    - 7.3.2.2.3. By Indication
- 7.3.3. Italy Advanced Therapy Medicinal Products CDMO Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Phase
    - 7.3.3.2.3. By Indication
- 7.3.4. France Advanced Therapy Medicinal Products CDMO Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Phase
    - 7.3.4.2.3. By Indication
- 7.3.5. Spain Advanced Therapy Medicinal Products CDMO Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Phase
    - 7.3.5.2.3. By Indication

8. Asia-Pacific Advanced Therapy Medicinal Products CDMO Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Phase
- 8.2.3. By Indication
- 8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Advanced Therapy Medicinal Products CDMO Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Phase
    - 8.3.1.2.3. By Indication
- 8.3.2. India Advanced Therapy Medicinal Products CDMO Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Phase
    - 8.3.2.2.3. By Indication
- 8.3.3. Japan Advanced Therapy Medicinal Products CDMO Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Phase
    - 8.3.3.2.3. By Indication
- 8.3.4. South Korea Advanced Therapy Medicinal Products CDMO Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By Phase
    - 8.3.4.2.3. By Indication
- 8.3.5. Australia Advanced Therapy Medicinal Products CDMO Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Phase
    - 8.3.5.2.3. By Indication

9. South America Advanced Therapy Medicinal Products CDMO Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Phase
- 9.2.3. By Indication
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Advanced Therapy Medicinal Products CDMO Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Phase
    - 9.3.1.2.3. By Indication
- 9.3.2. Argentina Advanced Therapy Medicinal Products CDMO Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Phase
    - 9.3.2.2.3. By Indication
- 9.3.3. Colombia Advanced Therapy Medicinal Products CDMO Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Phase
    - 9.3.3.2.3. By Indication

10. Middle East and Africa Advanced Therapy Medicinal Products CDMO Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Phase
- 10.2.3. By Indication
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Advanced Therapy Medicinal Products CDMO Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Phase
    - 10.3.1.2.3. By Indication
- 10.3.2. Saudi Arabia Advanced Therapy Medicinal Products CDMO Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Phase
    - 10.3.2.2.3. By Indication
- 10.3.3. UAE Advanced Therapy Medicinal Products CDMO Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Phase
    - 10.3.3.2.3. By Indication

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. Celonic AG
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
14.2. Rentschler Biopharma SE
14.3. Catalent, Inc.
14.4. Lonza Group AG
14.5. WuXi Advanced Therapies
14.6. Minaris Regenerative Medicine, LLC
14.7. Pluri Biotech Ltd.
14.8. REPROCELL USA Inc.
14.9. BioPhorum Operations Group
14.10. Cellares Corporation